安罗替尼治疗老年复发性肝门胆管癌1例报告

程思; 陈宝; 徐聂

doi:10.3969/j.issn.1001-5256.2020.06.032

安罗替尼治疗老年复发性肝门胆管癌1例报告

DOI: 10.3969/j.issn.1001-5256.2020.06.032

1. 彭州市中医医院肿瘤科
2. 成都中医药大学附属中西医结合医院成都市第一人民医院影像科
3. 成都中医药大学附属中西医结合医院成都市第一人民医院肿瘤二科

基金项目:

四川省卫生健康科研项目(19PJ174)；成都市医学科研课题(2019097)； 2019年四川省中医药服务能力提升“十百千”工程县级中医医院建设项目；

详细信息

中图分类号: R735.8
计量
- 文章访问数: 1005
- HTML全文浏览量: 12
- PDF下载量: 124
- 被引次数: 0
出版历程
- 出版日期: 2020-06-20

A case of recurrent hilar cholangiocarcinoma in the elderly treated with anlotinib

Research funding:

摘要

摘要:
<正>安罗替尼（anlotinib）是我国自主研发的新型多靶点小分子酪氨酸激酶抑制剂,能够抑制新生血管生成。相关动物试验[1]发现,安罗替尼能够抑制肿瘤生长,降低肿瘤内血管密度。2017年美国临床肿瘤学会年会[2]公布了安罗替尼三线治疗非小细胞肺癌的研究结果,与对照组比较总生存期显著延长（9. 6个月vs 6. 3个月）,为治疗晚期非小细胞肺癌提供了新的治疗选择。多项临床Ⅱ、Ⅲ期研究[3-5]显示,安罗替尼
- Klatskin肿瘤 /
- 老年人 /
- 分子靶向治疗
- Klatskin tumor /
- aged /
- molecular targeted therapy

HTML全文

参考文献(11)

[1] XIE C,WAN X,QUAN H,et al. Preclinical characterization of anlotinib,a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor[J]. Cancer Sci,2018,109(4):1207-1219.

[2] HAN B,LI K,WANG Q,et al. Effect of Anlotinib as a thirdline or further treatment on overall survival of patients with advanced non-small cell lung cancer:The ALTER 0303 phase 3randomized clinical trial[J]. JAMA Oncol,2018,4(11):1569-1575.

[3] WANG G,SUN M,JIANG Y,et al. Anlotinib,a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma[J]. Int J Cancer,2019,145(4):979-993.

[4] SUN YK,DU F,GAO M. Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer[J]. Thyroid,2018,28(11):1455-1461.

[5] ZHONG CC,CHEN F,YANG JL,et al. Pharmacokinetics and disposition of anlotinib,an oral tyrosine kinase inhibitor,in experimental animal species[J]. Acta Pharmacol Sin,2018,39(6):1048-1063.

[6] YIN XY. Controversy and strategy of preoperative biliary drainage reducing jaundice in hilar cholangiocarcinoma[J]. Chin J Dig Surg,2018,17(3):229-232.(in Chinese)殷晓煜．肝门部胆管癌术前行胆道引流术减轻黄疸的争议与策略[J]．中华消化外科杂志，2018,17(3):229-232.

[7] VALERO V,COSGROVE D,HERMAN JM,et al. Management of perihilar cholangiocareinoma in the era of multimodal therapy[J]. Expert Rev Gastroenterel Hepatol,2012,6(4):481-495.

[8] MURAKAMI Y,UEMURA K,SUDO T,et al. Perineural invasion in extrahepatic cholangiocarcinoma:Prognostic impact and treatment strategies[J]. J Gastrointest Surg,2013,17(8):1429-1439.

[9] CHEN XP,XIANG S. Therapy of hilar cholangiocarcinoma in the precise medicine period[J]. Chin J Dig Surg,2018,17(1):3-8.(in Chinese)陈孝平，项帅．精准医学时代肝门部胆管癌的治疗[J]．中华消化外科杂志，2018,17(1):3-8.

[10] YANG B,XIE H,WANG CP,et al. Study on inhibition of arotinib on human intrahepatic cholangiocarcinoma cell line HCCC-9810[J]. Chin J Med Guide,2017,19(12):1389-1391.(in Chinese)杨斌，谢辉，王春平，等．安罗替尼对人肝内胆管细胞癌细胞系HCCC-9810作用研究[J]．中国医药导刊，2017,19(12):1389-1391.

[11] ZHANG A,LIU B,XU D,et al. Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation:A case report[J]. Medicine(Baltimore),2019,98(52):e18435.

施引文献

资源附件(0)

访问统计